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Concomitant blockade of platelet-derived growth
factor receptors  and  induces intimal atrophy in
baboon PTFE grafts
Michael J. Englesbe, MD, Suzanne M. Hawkins, BS, Patrick C. H. Hsieh, MD, Gu¨nter Daum, PhD,
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Objective: Although current treatments for restenosis attempt to prevent the development of intimal hyperplasia, an
alternative strategy is to induce intimal atrophy after restenosis has developed. Because platelet-derived growth factor
(PDGF) is a smooth muscle cell growth and survival factor, we tested the hypothesis that complete blockade of PDGF by
using antibodies against PDGF receptors  and  would cause intimal atrophy in a baboon vascular graft model.
Methods: We administered chimeric antibodies against PDGF receptor  or PDGF receptor , either separately or
together, to baboons with bilateral prosthetic aortoiliac grafts, the intimas of which had reached maximal size before
treatment was begun. High blood flow, which we have previously shown to cause intimal atrophy, was induced through
one graft to serve as a positive control. After 2 weeks, the intima lining the grafts was assessed for cross-sectional area, cell
proliferation, and apoptosis by standard morphologic and immunohistochemical techniques.
Results: Blocking both PDGF receptors simultaneously reduced the cross-sectional area of the normal-flow graft intima
by 44% (P < .05 vs control), whereas treatment with the individual antibodies did not significantly alter intimal area.
Blockade of both receptors also inhibited smooth muscle cell proliferation by 66% (P < .05 vs control), whereas neither
antibody alone altered proliferation. In contrast, all treatments increased smooth muscle cell apoptosis threefold to
fivefold.
Conclusions: These data suggest that simultaneous inhibition of cell proliferation and stimulation of cell death by the
administration of antibodies to both PDGF receptor  and receptor  is required for intimal atrophy in this baboon graft
model. In addition, these data provide an in vivo model for the pharmacologic induction of intimal atrophy and introduce
a novel clinical approach to treat intimal hyperplasia. (J Vasc Surg 2004;39:440-6.)
Clinical Relevance: This study introduces the concept of pharmacologic induction of intimal atrophy. Intimal hyperplasia
plagues all forms of arterial reconstruction. Currently, the only effective treatment of these restenotic lesions is balloon
angioplasty or operative revision. An alternative approach to patients with clinically significant intimal hyperplasia might
be to stimulate intimal regression by modulating growth and survival factors required for intimal maintenance. Although
PDGF is known to be critical in intimal formation, the results of this study suggest that PDGF is also critical for intimal
maintenance. Inhibition of the PDGF system may prove to be a clinically applicable approach for inducing intimal
atrophy.
All forms of arterial reconstruction, including angio-
plasty, endarterectomy, stent angioplasty, and synthetic
and vein bypass grafting, frequently fail because of luminal
narrowing, a reduction of blood flow, and eventual throm-
bosis. Luminal narrowing (stenosis and restenosis) is a
consequence of intimal hyperplasia and pathologic remod-
eling. Restenosis after angioplasty is primarily due to patho-
logic remodeling, whereas restenosis after prosthetic graft-
ing and stent angioplasty is caused by intimal hyperplasia
alone. Because intimal hyperplasia affects 15% to 30% of all
arterial interventions, strategies to control this injury re-
sponse should have significant clinical effect.1
Pharmacologic agents to prevent restenosis have re-
cently been developed, including rapamycin (sirolimus),2
Taxol (paclitaxel),3 E2 promoter binding factor (E2F)
transcription factor decoy oligonucleotides,4 and hepa-
rins.5 These treatments focus on preventing intimal hyper-
plasia. An alternative approach is to stimulate regression of
existing intimal lesions. This approach would enable the
clinician to treat only those patients who develop resteno-
sis. We have previously shown in a baboon arterial bypass
graft model that supranormal shear stress causes intimal
atrophy, demonstrating proof of principle.6,7 In addition,
intimal hyperplasia in this graft model is dependent on
platelet-derived growth factor (PDGF),8 and the PDGF-A
and -B chain ligands, as well as the PDGF receptors (PDG-
FRs)  and , have been found in the graft intima.9
The PDGF family is composed of a group of disulfide-
bonded dimeric isoforms (PDGF-AA, -AB, -BB, -CC, and
-DD) that regulate growth, survival, and function in
smooth muscle cells (SMCs) by binding to dimers of two
receptor tyrosine kinases. The PDGF receptor  binds
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PDGF-A, PDGF-B, and PDGF-C, whereas PDGF receptor
 binds PDGF-B and PDGF-D.10,11 PDGF ligands and
receptors play a clear role in fetal vascular development,
which is governed by a balance between cell proliferation
and matrix protein synthesis on one hand and cell death and
matrix degradation on the other hand.12-15 PDGF receptor
–deleted Patch mice have abnormal cardiovascular devel-
opment and reduced numbers of SMCs in the vessel wall.16
Targeted disruption of the PDGF receptor  gene leads to
the formation of blood vessels lacking SMCs.17 In addition
to a role in prosthetic grafts as discussed earlier, PDGF is
also involved in intimal formation following arterial inju-
ry.18-20 All of these observations plus the fact that PDGF is
not only an SMC mitogen but also a potent survival factor
for SMCs in vitro21,22 suggest that inhibition of PDGF
receptors might stimulate atrophy of the neointima after
luminal narrowing has developed. We have tested this
hypothesis in baboon prosthetic vascular grafts.
METHODS
Antibodies. Chimeric versions of monoclonal anti-
bodies against human PDGF receptor  and PDGF recep-
tor , with the variable domains of the mouse heavy and
light chains and the constant domains of human immuno-
globulin G4 (IgG4) and  for the heavy and light chains,
respectively, were made as described by Celltech Therapeu-
tics, Ltd (Slough, UK).23,24
In vivo effects of PDGF receptors  and  blockade.
Twenty-four male, juvenile baboons (Papio cynocephalus)
(weighing approximately 10 kg each) received bilateral,
aortoiliac, 4.0-mm polytetrafluoroethylene (PTFE) bypass
grafts (W. L. Gore and Associates, Wilmington, Del) with
ligation of the intervening native vessels, as previously
described.8 Eight weeks after implantation, a positive con-
trol for intimal regression was established by inducing high
flow through the left graft by placement of a femoral
arteriovenous (A-V) fistula. At this time and on postoper-
ative days 4 and 9, animals received (intravenously) either
vehicle alone (n  7), PDGF receptor  antibody (20
mg/kg, n  6), PDGF receptor  antibody (20 mg/kg, n
 4), or PDGF receptor  and PDGF receptor  antibodies
(10 mg/kg of each, n  7). Antibody levels in blood
samples taken immediately prior to each antibody dose and
at the time of animal sacrifice were quantified by enzyme-
linked immunosorbent assay (ELISA).20 Flow rates and
graft and arterial diameters were quantified by duplex ul-
trasound scanning, as previously described.8 At 17, 9, and 1
hour prior to death, the baboons were given bromode-
oxyuridine (BrdU; 30 mg/kg IM; Roche, Basel, Switzer-
land). On postoperative day 14, the animals were killed
(pentobarbital overdose) and perfusion was fixed (90
mmHg) with 10% formalin. This protocol was approved by
the Animal Care Committee at the University of Washing-
ton, and animal care followed established guidelines.25
Morphology. Morphometric measurements were
conducted as previously described, with operators blinded
to animal identity.8,26
Immunohistochemistry. Immunostaining of cells
positive for BrdU and terminal deoxynucleotidyl trans-
ferase–mediated dUTP nick-end labeling (TUNEL) was
performed as previously described.8 Apoptotic cells were
also stained by using a monoclonal antibody against single-
stranded DNA (1 g/mL; Chemicon International, Te-
mecula, Calif). Macrophages were stained by using a mouse
anti-human macrophage (HAM 56) antibody (1 g/mL;
Enzo Biochem, Syosset, NY). T cells were stained by using
rabbit anti-human CD3 (10 g/mL; DAKO Corp,
Glostrup, Denmark). Endothelial cells were stained by
using a rabbit anti-human CD31 antibody (1 g/mL;
DAKO Corp). SMCs were stained by using a mouse anti-
human smooth muscle -actin antibody (0.1 g/mL;
Sigma Chemical, St Louis, Mo). Staining was performed by
using the avidin-biotin-peroxidase method (Vector Labo-
ratories, Burlingame, Calif) with a hematoxylin
counterstain.20
Statistical analysis. All data are expressed as the mean
 SE of the mean. The significance of differences was
determined by using the Mann-Whitney rank-sum test with
the Bonferroni correction for multiple comparisons. P 
.05 was considered significant.
RESULTS
Serum antibody levels. We determined serum chi-
meric antibody levels on serum samples obtained on days 4,
9, and 14 (Table I). Serum levels of the antibody to PDGF
receptor  fell below the target level (20 g/mL) after 14
days in both groups receiving this antibody.
High-flow control. Placement of the femoral A-V
fistula as a positive control for atrophy7 increased shear
stress in the ipsilateral graft (Table II) and iliac artery (Table
III) and decreased graft intimal area compared with the
normal-flow graft (2.15 0.21 vs 3.21 0.38; P .010).
There were no significant differences in shear stress be-
tween the control and antibody treated groups (Tables II,
III).
Intimal morphology. Two weeks of treatment with
antibodies to both PDGF receptor  and PDGF receptor 
significantly induced intimal regression in the normal-flow
grafts (Fig 1, 2). In contrast, treatment with antibody to
PDGF receptor  or to PDGF receptor  alone had no
significant effect on intimal area. Simultaneous blockade of
PDGF receptor  and PDGF receptor  also significantly
reduced the number of intimal nuclei and nuclear density
(Table II). Blockade of PDGF receptor  reduced the
nuclear density compared with control, but it had no effect
on the total number of intimal nuclei (Table II). Neither
the combination of antibodies (Table III) nor the individ-
ual antibodies (data not shown) had a significant effect on
the intima of the iliac arteries.
In contrast to normal flow, administration of either the
combination of antibodies or anti–PDGF receptor  alone
decreased intimal area of high-flow grafts compared with
the high-flow control (1.14  0.19 and 1.17  0.06,
respectively, vs 2.15  0.21; P  .02).
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Intimal cell apoptosis. In both the normal- and high-
flow grafts, treatment with the PDGF receptor antibodies
in combination or separately significantly increased
TUNEL-positive staining compared with the appropriate
flow control (Fig 3). These results were confirmed by
ssDNA staining (data not presented). In contrast, there was
no positive TUNEL or ssDNA staining in the media or
intima of the normal- or high-flow iliac arteries (data not
presented).
Because TUNEL and ssDNA staining was observed in
the deep intima adjacent to the graft,6 which contains
numerous inflammatory cells,8,27 there is the possibility
that inflammatory cells contribute to SMC apoptosis in-
creased by treatment. However, the number of macro-
phages and T cells (.01%) present in the intima was not
altered by any of the treatments (data not presented). In
addition, there was no difference in the distribution of
apoptotic cells between the groups.
Intimal cell proliferation. In both the normal- and
high-flow grafts, simultaneous treatment with both PDGF
receptor antibodies significantly reduced BrdU staining,
whereas treatment with antibody to PDGF receptor  or 
alone had no significant effect (Fig 4). The BrdU-posi-
tive cells were SMCs primarily found in the superficial
intima, just beneath the endothelium, a distribution not
altered by treatment. There was no BrdU-positive stain-
ing in the media or intima of the iliac arteries (data not
presented).
DISCUSSION
We have demonstrated that simultaneous blockade of
PDGF receptors  and , but not blockade of either
receptor alone, significantly induced atrophy of an endo-
thelialized neointima in baboon PTFE grafts under normal
blood flow conditions. This intima is fully formed after 2
months and does not change in size at later times.7,27 The
increased SMC apoptosis and decreased SMC proliferation
caused by the combination of blocking antibodies led to
decreased numbers of intimal SMCs in the graft, but not in
the adjacent iliac artery. This difference is important from a
clinical perspective, because atrophy of normal arterial in-
tima or media would be undesirable.
















High flow 79.7  7.7 96.2  8.7 105.4  3.8 95.5  12.4
Normal flow 21.2  3.7 27.2  2.8 24.8  4.3 28.6  5.9
Total nuclei
High flow 7368  890 4142  328 4101  349 3101  492*
Normal flow 9229  1538 5465  1006 7741  208 4162  276*
Nuclear density
(nuclei/mm2)
High flow 3490  306 2459  257* 3534  246 2862  277*
Normal flow 2760  237 2098  202* 2923  269 2177  325*
Comparisons made within flow groups (i.e. control normal flow to anti-PDGFR- normal flow)
*P  .05 vs control.








PDGFR- group 107  7 NA 107  7
PDGFR- group NA 72  14 72  14
PDGFR-   group 28  11 30  11 58  11
Day 9
PDGFR- group 64  19 NA 64  19
PDGFR- group NA 58  12 58  12
PDGFR-   group 21  8 31  7 52  8
Day 14
PDGFR- group 9  6 NA 9  6
PDGFR- group NA 75  6 75  6
PDGFR-   group 4  1 20  9 24  4
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The reasons for the difference in response of the arterial
intima and of the PTFE graft intima to anti–PDGF receptor
 and anti–PDGF receptor  blockade are not clear, al-
though there are several possibilities. First, cell tension and
shape regulate cell proliferation and other cellular process-
es.28 Stretch forces are present in the artery but probably
not in the noncompliant graft. Second, in contrast to the
artery, the graft intima is not a quiescent vascular tissue, as
both SMCs and endothelial cells are proliferating and dying
at rates far greater than those observed in the native artery.
This condition may result from a foreign body response to
the PTFE. Although macrophages and lymphocytes do not
infiltrate into the intima in great numbers, they populate
the granulation tissue within the pores of the graft. Diffu-
sion of inflammatory factors may alter the SMC response to
growth factors (and conversely, the response to the removal
of growth factor stimulation). For example, interleukin 1
(IL-1) inhibits aortic SMC migration while augmenting
SMC mitogenesis induced by PDGF-BB.29 Another factor
is that graft intimal SMCs are derived from capillaries
growing through the graft, and pericytes and arterial SMCs
have different properties.30,31
Blockade of PDGF receptors  and  individually or
simultaneously increased apoptosis in both normal- and
high-flow grafts. Consistent with this finding, PDGF-B
chain blocking aptamers and cyclic peptide analogues of
PDGF-BB also increase apoptosis,32,33 and previous find-
ings in the baboon graft model demonstrated that PDGF
receptor  was involved in cell survival.8 In contrast to
apoptosis, proliferation was decreased only by the simulta-
neous blockade of PDGF receptors  and -. Our data
suggest that inhibition of proliferation, as well as stimula-
tion of apoptosis, is required for regression of the graft
intima. Indeed, this inhibition occurs when grafts are
switched to high flow.6 In contrast to the normal-flow
situation, when blood flow was high, blockade of only
PDGF receptor was needed to cause atrophy, presumably
because proliferation was inhibited by high flow. The sim-
plest explanation for this observation is that high shear
stress decreases levels of PDGF receptor . However, pre-
liminary analysis with microarrays showed that PDGF re-
ceptor  mRNA expression in the graft intima was not
altered for at least 7 days after increasing shear stress (Hsieh
et al, Jan 2003, unpublished results). Another possibility is
that high shear inhibits PDGF receptor  signaling, either
directly or indirectly by signaling molecules generated by
high shear. For example, nitric oxide (NO), which is in-
duced by high shear,7 can inhibit PDGF-regulated cell-
cycle molecules.34
One possible explanation of why PDGF receptor 
must be blocked along with PDGF receptor  to block
proliferation in normal-flow graft comes from investiga-
tions of the recently described PDGF family members
PDGF-CC and -DD. In vitro, PDGF-CC markedly in-
duces SMC proliferation, an effect which is inhibited by
chimeric anti–PDGF receptor  and not by anti–PDGF
receptor  (G.D., unpublished data). Although not as
potent, PDGF-AA–mediated proliferation is also inhibited by
both antibodies.35 PDGF-D chain binds to PDGF receptor,
but not to PDGF receptor .10 We have previously shown
that PDGF receptors  and - and PDGF-A chain are present
in the graft intima, whereas PDGF-B chain is nearly undetect-
able.9 PDGF-CC and -DD may also be present in the graft
intima, thus requiring blockade of both of the PDGF
receptors to cause a clinically significant response.
The role of PDGF in SMC migration, proliferation,
apoptosis, and matrix accumulation—major steps in intimal
formation—has been defined in various models. Intimal
formation after arterial injury in rats, rabbits, pigs, and
nonhuman primates requires PDGF receptor , but not
PDGF receptor .8,18,19 PDGF receptor  can antagonize
the pro-migratory properties mediated by PDGF receptor
 when SMCs are grown on some, but not all, extracellular
matrix proteins.36,37 Although SMC migration clearly
Table III. Morphologic and immunohistochemical data









High flow 90.9  6.2 79.1  7.3
Normal flow 36.2  6.8 44.3  8.0
Iliac intimal area
(mm2)
High flow 0.024  0.002 0.024  0.002
Normal flow 0.023  0.002 0.024  0.004
Total nuclei
High flow 74.4  7.9 72.0  11.0
Normal flow 71.3  9.6 75.3  10.4
Nuclear density
(nuclei/mm2)
High flow 3102  457 2998  480
Normal flow 3100  629 3139  450
There were no significant differences between the control and antibody
treated groups.
Fig 1. Intimal area of high-flow (black) and normal-flow (gray)
PTFE grafts 2 weeks after initiation of treatment with carrier
medium (control) or antibodies to PDGF receptors  or  or to
both (*P  .05 vs appropriate flow control). PDGFR, Platelet-
derived growth factor receptor.
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plays an important role in intimal formation by means of
capillary growth through the graft, its role in intimal main-
tenance is not known. Additionally, the role of PDGF in
angiogenesis38 suggests the possibility that blockade of the
PDGF receptors may decrease the number of capillaries in
the intima and graft matrix, leading to ischemia and, ulti-
mately, atrophy of the intima. However, significant num-
bers of endothelial cells (CD31) were not observed in the
intima, and the number in the graft matrix itself was not
altered by blockade of the PDGF receptors (M.E., unpub-
lished data).
Intimal regression mediated by high blood flow leads
to a proportional loss of cells and matrix,6,7 with the loss of
matrix mediated, in part, by serine proteinases, including
plasmin.39 There is a loss of proteoglycans after the switch
to high flow (Kenagy et al, unpublished observation), but
this loss was not observed after treatment with the antibod-
ies to PDGFR (Kenagy et al, unpublished observations). In
contrast to high flow alone, treatment with anti–PDGF
receptor , with or without anti–PDGF receptor , leads to
a decrease in nuclear density, suggesting that loss of cells
caused by PDGF receptor  is not accompanied by a
proportionate loss of matrix. The reason for this decrease is
not clear. In some cells, including endothelial cells,40 apo-
ptotic cells activate and increase the levels of matrix-degrad-
ing proteinases, including plasminogen activators, thus
providing a linkage between cell death and matrix degrada-
tion. Whether such a pathway is deficient after treatment
with anti–PDGF receptor  requires further study.
Intimal hyperplasia is a progressive disease and might
recur following treatment with antibodies to induce atro-
phy. Unfortunately, serum antibody levels of the PDGF
receptor  fall significantly after 14 days of treatment and,
despite continued doses, are not detectable by 28 days.8
Fig 2. Histologic cross sections of normal flow PTFE grafts at 2 weeks after initiation of treatment with vehicle control
(A), blocking antibodies to PDGF receptor  (B), blocking antibodies to PDGF receptor  (C), or blocking antibodies
to both PDGF receptors  and  (D) (hemotoxylin-eosin, 	16 magnification).
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Thus, long-term experiments with the chimeric PDGF
receptor antibodies are not practical. The use of small
molecule inhibitors of PDGF receptor kinase activity might
allow long-term PDGF receptor inhibition in order to
address the question of long-term effects.
In conclusion, even though blockade of PDGF recep-
tor  is sufficient to inhibit intimal formation, maximal
induction of intimal atrophy requires blockade of PDGF
receptors  and -. We suggest that both PDGF receptors
 and - are required for the maintenance of the intima in
baboon PTFE grafts. The observation that blockade of
PDGF receptors  and - stimulates regression of an estab-
lished intima introduces an exciting new strategy for treat-
ing intimal hyperplasia.
Limitations. Blockade of PDGF receptor  resulted
in a mean intimal size 20% less than control, whereas
blockade of PDGF receptor  led to a mean intimal size
10% less than control. The power to detect differences of
this magnitude would require much larger numbers of
animals in each group. Thus, it is possible that the effects on
intimal size of each antibody are real and additive.
We thank Sameer S. Jejurikar, MD, for assistance with
manuscript preparation. Chimeric antibodies were pro-
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